HRMY · XBRL financial data

Harmony Biosciences Holdings financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (HRMY's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	160	305	438	582	715	868
Cost of goods and services sold	28	56	83	121	157	198
Gross profit	132	250	354	461	558	670
Research and development	19	30	71	76	146	190
General and administrative	40	64	84	95	110	153
Total operating expenses	115	162	234	269	367	462
Operating income (loss)	17	88	120	192	191	208
Interest expense	29	24	19	24	17	15
Other income (expense)	(3)	0	0	0	(0)	(1)
Income tax expense (benefit)	—	3	(77)	45	46	56
Net income (loss)	(37)	35	181	129	145	159
Earnings per share, basic USD per share	(2.48)	0.60	3.07	2.17	2.56	2.76
Earnings per share, diluted USD per share	(2.48)	0.58	2.97	2.13	2.51	2.71
Weighted average shares, basic millions of shares	26	58	59	59	57	57
Weighted average shares, diluted millions of shares	26	59	61	60	58	59

Fiscal years (HRMY's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	229	234	244	312	453	753
Short-term investments	—	—	79	42	14	23
Accounts receivable	22	35	55	74	83	97
Inventory	4	4	4	5	7	5
Total current assets	263	284	400	451	579	907
Property and equipment, net	1	1	1	0	1	—
Right-of-use asset	—	3	2	2	2	5
Total assets	427	433	674	811	999	1,272
Accounts payable	3	1	4	18	14	18
Accrued liabilities	123	40	60	99	121	191
Current portion of long-term debt	—	2	2	15	16	20
Total current liabilities	135	54	79	164	175	252
Long-term debt	194	190	190	179	163	144
Lease liability, non-current	—	2	1	1	1	5
Total liabilities	330	247	271	344	340	401
Retained earnings (accumulated deficit)	(488)	(454)	(272)	(143)	2	161
Total stockholders' equity	97	187	403	467	659	870
Total liabilities and equity	427	433	674	811	999	1,272
Common shares outstanding (cover page) millions of shares	57	59	60	57	57	58

Fiscal years (HRMY's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(37)	35	181	129	145	159
Stock-based compensation	5	16	26	32	43	45
Net cash from operating activities	(3)	99	144	219	220	348
Purchases of property and equipment	0	0	0	0	1	0
Net cash from investing activities	(2)	(100)	(142)	(46)	(67)	(40)
Proceeds from issuing common stock	135	30	—	—	—	—
Share repurchases	0	—	—	100	—	—
Proceeds from long-term debt	200	200	—	200	—	—
Repayments of long-term debt	—	1	2	5	15	16
Net cash from financing activities	209	7	7	(106)	(11)	(9)
Net change in cash	204	6	9	67	141	300

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Harmony Biosciences Holdings	550	261	92*	58.2M	—	Q2 FY26 10-QJun 30, 2026
Travere Therapeutics	124	225	98*	96.0M	—	Q3 FY26 10-QSep 30, 2026
Ani Pharmaceuticals	360	266	57*	not reported	—	Q2 FY26 10-QJun 30, 2026
Celldex Therapeutics	47	0	(57)*	78.5M	12.5 quarters	Q2 FY26 10-QJun 30, 2026
Adaptive Biotechnologies	170	72	(6.4)*	159.6M	53.8 quarters	Q2 FY26 10-QJun 30, 2026
Innoviva	570	120	52*	72.2M	—	Q2 FY26 10-QJun 30, 2026
Arrowhead Pharmaceuticals	55	75	(177)*	141.3M	9.0 quarters	Q3 FY26 10-QJun 30, 2026
Mannkind	53	109	(18)*	321.5M	6.0 quarters	Q2 FY26 10-QJun 30, 2026
Schrodinger	288	59	(34)*	not reported	12.1 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.